{
    "nctId": "NCT01038258",
    "briefTitle": "Monitoring Response After The First Chemotherapy Cycle After Neoadjuvant Breast Cancer Therapy",
    "officialTitle": "Monitoring Response After The First Chemotherapy Cycle In Newly Diagnosed Breast Cancer As A Guide For Neoadjuvant Therapy",
    "overallStatus": "UNKNOWN",
    "conditions": "Invasive Ductal Carcinoma, Lobular Breast Carcinoma, Inflammatory Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "Pathologic response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Recently diagnosed breast carcinoma that will receive neoadjuvant chemotherapy based on: Tumors size greater than 2 cms; Locally advanced tumors, Tumors close to or invading chest wall or areola and/or Inflammatory Breast cancer.\n* 18 years of age.\n* Available for follow-up visits\n* Able to comply with study requirements.\n* Have signed an IRB approved written informed consent form\n\nExclusion Criteria:\n\n* Any significant medical or psychiatric illness, which would prevent the patient from giving informed consent or following the study procedures.\n* Pregnant and Nursing women.\n* No restriction will be placed on the chemotherapy regimen used although we expect that most patients will receive Anthracycline based regimens.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}